Caribou Biosciences vs CRISPR Therapeutics
CRBU and CRSP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and CRSP compare
CRISPR Therapeutics is the larger company, worth 105 times as much as Caribou Biosciences ($4.1B against $38.8M).
Caribou Biosciences grew revenue faster over the last twelve months (1.6% versus −34.3% for CRISPR Therapeutics).
Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1085% compared with −1812% at CRISPR Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | CRSP |
|---|---|---|
| Size and price | ||
| Market cap | $38.8M | $4.1B |
| Share price | $0.362 | $42.24 |
| Change, 1 year | −84.0% | −19.1% |
| Change, 5 years | −98.3% | −48.8% |
| Beta (5Y) | 1.94 | 1.38 |
| Employees | 97 | 393 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.1× (better) | 162× |
| P/B | 0.5× (better) | 2.5× |
| FCF yield | −240% | −9.2% (better) |
| Fair value | $1.08 | – |
| Margin of safety | 66.4% | – |
| Growth | ||
| Revenue growth (TTM) | 1.6% (better) | −34.3% |
| Revenue growth, 5Y average | −2.0% | 37.3% (better) |
| Profitability | ||
| Operating margin | −1141% (better) | −2115% |
| Net margin | −1085% (better) | −1812% |
| FCF margin | −985% (better) | −1497% |
| Return on equity | −93.8% | −25.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.97 | 16.21 (better) |
| Altman Z-score | −9.18 | 1.78 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | −69.3% | −2.7% (better) |
| Shareholder yield | −69.3% | −2.7% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 78.9% |
| Held by insiders | 5.7% | 2.7% |
| Insider net buying, 12 months | −$47.5K (better) | −$17.9M |
| Short interest, % of float | 14.7% | 18.3% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- CRSP stock overview
- CRSP income statement
- CRSP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.